富蘭克林坦伯頓全球投資系列-生技領航基金美元F(acc)股
12.47美元0.38(2.96%)
2025/02/07更新
績效 / 1月3.13%
3月8.87%
1年1.53%
晨星評等-
- 1.現金2.76%
- 2.股票13.78%
- 3.債券0.00%
- 4.其他83.46%
- 1.美國83.04%
- 2.歐元區5.34%
- 3.英國4.26%
- 4.歐洲不包含歐元區3.26%
- 5.加拿大0.93%
- 1.Amgen Inc6.05%
- 2.Vertex Pharmaceuticals Inc5.82%
- 3.Gilead Sciences Inc5.64%
- 4.Regeneron Pharmaceuticals Inc5.57%
- 5.Intra-Cellular Therapies Inc3.73%
- 6.argenx SE ADR3.51%
- 7.Jazz Pharmaceuticals PLC3.36%
- 8.Neurocrine Biosciences Inc2.86%
- 9.AstraZeneca PLC ADR2.83%
- 10.Merus NV2.65%
- 1.現金2.76%
- 2.股票13.78%
- 3.債券0.00%
- 4.其他83.46%
- 1.美國83.04%
- 2.歐元區5.34%
- 3.英國4.26%
- 4.歐洲不包含歐元區3.26%
- 5.加拿大0.93%
- 1.Amgen Inc6.05%
- 2.Vertex Pharmaceuticals Inc5.82%
- 3.Gilead Sciences Inc5.64%
- 4.Regeneron Pharmaceuticals Inc5.57%
- 5.Intra-Cellular Therapies Inc3.73%
- 6.argenx SE ADR3.51%
- 7.Jazz Pharmaceuticals PLC3.36%
- 8.Neurocrine Biosciences Inc2.86%
- 9.AstraZeneca PLC ADR2.83%
- 10.Merus NV2.65%